相关实验视频

Updated: Feb 26, 2026

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis

Published on: March 9, 2015

巴里西提尼布对指甲脱毛区域的有效性:为期48周的单中心回顾性研究

Michela Starace^1,2, Francesca Pampaloni^3,4, Federico Quadrelli^1,2

¹Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Via Massarenti 1, 40138, Bologna, Italy.

Clinical drug investigation

|February 24, 2026

概括

巴里西替尼有效地治疗严重脱发区 (AA) 的指甲问题,改善指甲的外观并减少受影响的指甲. 这种Janus激酶抑制剂对管理AA指甲疾病充满希望,尽管头发和指甲的改善没有强烈的相关性.

科学领域:

皮肤病学皮肤病学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

脱发性白发症 (AA) 是一种自身免疫性疾病,导致无痕的脱发.
爪影响高达66%的AA患者,特别是那些患有严重疾病或儿童.
在AA中指甲的变化包括轨道,穴位和白血.

研究的目的:

为了评估巴里西提尼布4毫克/天在治疗严重脱发症的指甲表现的疗效.
用标准化的临床评估来评估巴里西提尼布对指甲异常的影响.

主要方法:

对37名患有严重的AA (SALT分数>50) 和指甲干扰的患者进行了回顾性研究.
用巴里西提尼布4毫克/天治疗48周.
通过SALT评分,乳镜和临床报告结果 (ClinRO) 来评估指甲的外观.

主要成果:

观察到指甲异常的显著改善,受影响指甲的平均数量从6.4降至2.1 (p < 0.001).
对于指甲外观的ClinRO得分显示了显著的改善 (p < 0.001).
头发的再生和指甲的改善之间存在微弱且不显著的相关性 (r = 0.15,p = 0.6),这表明反应有差异.

结论:

巴里西提尼布是一种有前途的治疗方法,用于治疗白发性脱毛的指甲.
建议在AA患者中进行例行指甲评估.
需要对更大的样本大小和长期数据进行进一步的研究,以改进对AA指甲病的评估工具.

更多相关视频

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Published on: January 27, 2018

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...